Venture capital investors Zeeuws Investerings Fonds and Participatiemaatschapij Oost Nederland have joined forces with national and regional partners to fund development and sales of MIMETAS’ unique 3D disease- and tissue modelling technologies.
Jos Joore, co-founder and Chief Business Officer of MIMETAS, acknowledges that these resources arrive at a strategically important moment: "Collaborations with top-tier pharmaceutical companies are expanding rapidly, an example of this is the recently announced 1.6 million dollar kidney-on-a-chip project with Roche, Pfizer and GlaxoSmithKline. The funds will be used to scale up the production of OrganoPlatesTM and strengthen our activities in predictive preclinical model development, thus consolidating our leadership in this highly competitive field."
MIMETAS (www.mimetas.com) has been founded by Paul Vulto, Thomas Hankemeier and Jos Jore to develop organ-on-a-chip technology for drug screening in 3D-tissues. MIMETAS has developed a unique microfluidic platform enabling testing of compounds in high throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The MIMETAS OrganoPlateTM platform supports 3D cell culture under continuous perfusion, membrane-free co-culture and boundary- and gradient formation, thus mimicking the important aspects of tissues and organs. MIMETAS develops and validates customised disease-, toxicology- and transport tissue models.